Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Rhea-AI Summary

Bausch + Lomb to present at AAOpt annual meeting, highlighting the results of a study on Blink Triple Care Lubricating Dry Eye Drops and data on MIEBO prescription eye drops and INFUSE Multifocal contact lenses. Educational events will also be hosted.

Positive

• Bausch + Lomb's presentations and educational events at AAOpt annual meeting could generate interest and showcase the company's innovative eye health products.
• Blink Triple Care Lubricating Dry Eye Drops study results could positively impact stock price.

Negative

• None.

Presentations Will Feature Blink^® Triple Care Lubricating Dry Eye Drops, MIEBO™ (perfluorohexyloctane ophthalmic solution) and Bausch + Lomb INFUSE^® Multifocal Lenses

Company Will Host Seven Educational Events

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced one podium presentation and four poster presentations during the American Academy of Optometry (AAOpt) annual meeting, which will take place in New Orleans Oct. 11-14, 2023.

The podium presentation will highlight the results of a prospective, multi-center study that evaluated key clinical dry eye disease (DED) findings in patients using Blink Triple Care Dry Eye Lubricating Eye Drops. Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Two poster presentations will include data on the newly launched MIEBO prescription eye drops, including an evaluation of the distribution and retention of MIEBO on the human eye and an analysis of the effect of MIEBO on fluorescein staining across all regions of the cornea. Additionally, two posters will feature data on Bausch + Lomb INFUSE Multifocal silicone hydrogel daily disposable contact lenses, which launched in June, including an evaluation of the lens’ clinical performance and an assessment of patient responses to the lens.

Bausch + Lomb will also host several educational events during the meeting featuring MIEBO eye drops, the new LUMIFY EYE ILLUMINATIONS™ product line, LOTEMAX^® SM (loteprednol etabonate ophthalmic gel) 0.38% and VYZULTA^® (latanoprostene bunod ophthalmic solution) 0.024%. Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.

The Bausch + Lomb schedule at AAOpt:

Podium Presentation

• “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.

Poster Presentations

• “Clinical Performance of a Novel Daily Disposable Silicone Hydrogel Multifocal Contact Lens.” Schafer et al.
• “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.
• “Presbyopic Patient Assessment of a New Daily Disposable Silicone Hydrogel Multifocal Contact Lens.” Rah et al.
• “Visualization of MIEBO, an Eye Drop for Dry Eye Disease, on the Human Ocular Surface Using Infrared Emisivity.” Borchman et al.

Featured Educational Events

Wednesday, October 11

• “Industry Innovation Lunch and Learn”
  12-12:55 p.m. CT at the Ernest N. Morial Convention Center (900 Convention Center Blvd., New Orleans; Room R06, second floor)
  Gina Wesley, O.D., John Womack, O.D., and Doug DeVries, O.D., will share practical patient cases using products from across the Bausch + Lomb consumer, vision care and pharmaceutical portfolios.

• “Showcasing Inflammation and IOP Control”
  6:45 p.m. CT at Palace Café (605 Canal Street, New Orleans; room Fleur de Lis)
  Michael Chaglasian, O.D., and Nora Cothran, O.D. will discuss the benefits of using LOTEMAX^® SM (loteprednol etabonate ophthalmic gel), 0.38%, and VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024%. Register in advance.

Thursday, October 12

• “Introducing New LUMIFY EYE ILLUMINATIONS”
  8:00-8:45 a.m. CT at Hilton New Orleans Riverside (Two Poydras Street, New Orleans; room Royal)
  Join Gina Wesley, O.D., to discover LUMIFY EYE ILLUMINATIONS, a new specialty eye care line.

• “Innovations in Inflammation and IOP Control”
  8:00-8:45 a.m. CT at Hilton New Orleans Riverside (Two Poydras Street, New Orleans; room Camp)
  Derek Cunningham, O.D., will discuss the benefits of using LOTEMAX^® SM (loteprednol etabonate ophthalmic gel), 0.38%, and VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024%.

• “Fighting the Battle in the Rx Treatment of Evaporative Dry Eye Disease: Introducing MIEBO (Perfluorohexyloctane Ophthalmic Solution)”
  6:00 p.m. CT at the National World War II Museum (1043 Magazine Street, US Freedom Pavilion, New Orleans)
  Learn about MIEBO, the first and only prescription eye drop that directly targets tear evaporation, as well as the results of the MIEBO pivotal phase 3 studies. Register in advance.

Friday, October 13

• “MIEBO (perfluorohexyloctane ophthalmic solution): A Newly Approved Product”
  8:00-8:45 a.m. CT at Hilton New Orleans Riverside Hotel (Two Poydras Street, New Orleans; room Canal)
  Tear evaporation is the leading cause of dry eye disease. Join James Deom, O.D., to learn more about MIEBO, the first and only prescription eye drop that directly addresses tear evaporation.

• “A New Orleans Nightcap with LUMIFY EYE ILLUMINATIONS”
  8:30-10:30 p.m. CT at the Gallery Venue (755 Tchoupitoulas Street, New Orleans)
  Celebrate the launch of LUMIFY EYE ILLUMINATIONS and learn about these new clinically proven products from Selina McGee, O.D. Register in advance.

Important Safety Information for MIEBO

INDICATION

MIEBO™ (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

• Patients should remove contact lenses before using MIEBO™ and wait for at least 30 minutes before reinserting.
• It is important for patients to use MIEBO exactly as prescribed.
• It is not known if MIEBO™ is safe and effective in children under the age of 18.
• The most common eye side effect seen in studies was blurred vision (1% to 3 % of patients reported blurred vision and eye redness).

Click here for full Prescribing Information for MIEBO.

Important Safety Information for LOTEMAX SM

INDICATION

LOTEMAX SM (loteprednol etabonate ophthalmic gel) 0.38% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

IMPORTANT SAFETY INFORMATION

• LOTEMAX SM, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
• Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If LOTEMAX SM is used for 10 days or longer, IOP should be monitored.
• Use of corticosteroids may result in posterior subcapsular cataract formation.
• The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those with diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
• Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infections.
• Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).
• Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal cultures should be taken when appropriate.
• Contact lenses should not be worn when the eyes are inflamed.
• There were no treatment-emergent adverse drug reactions that occurred in more than 1% of subjects in the three times daily group compared to vehicle.

Click here for full Prescribing Information for LOTEMAX SM.

Important Safety Information for VYZULTA

INDICATION

VYZULTA (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

• Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
• Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
• Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
• Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
• There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
• Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
• Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

Please click here for full Prescribing Information.

Patients are encouraged to report negative side effects of these prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

© 2023 Bausch + Lomb.

MTB.0285.USA.23

View source version on businesswire.com: https://www.businesswire.com/news/home/20231004560490/en/

Media Contact:

Kristy Marks

kristy.marks@bausch.com

(908) 927-0683

Investor Contact:

George Gadkowski

george.gadkowski@bausch.com

(877) 354-3705 (toll free)

(908) 927-0735

Source: Bausch + Lomb